Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Biocryst Pharma Inc (BCRX)

3.945   -0.055 (-1.38%) 08-07 14:55
Open: 4 Pre. Close: 4
High: 4.03 Low: 3.81
Volume: 5,248,021 Market Cap: 696M
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.145 - 4.178 4.178 - 4.201
Low: 3.793 - 3.829 3.829 - 3.853
Close: 3.952 - 4.009 4.009 - 4.047

Technical analysis

as of: 2020-08-07 2:24:21 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 6.05     One year: 7.04
Support: Support1: 3.81    Support2: 3.17
Resistance: Resistance1: 5.18    Resistance2: 6.03
Pivot: 4.40
Moving Average: MA(5): 4.14     MA(20): 4.57
MA(100): 3.99     MA(250): 3.24
MACD: MACD(12,26): -0.20     Signal(9): -0.12
Stochastic oscillator: %K(14,3): 9.83     %D(3): 14.32
RSI: RSI(14): 34.68
52-week: High: 6.29  Low: 1.38  Change(%): 46.4
Average Vol(K): 3-Month: 772356  10-Days: 677899

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
BCRX has closed above bottom band by 10.7%. Bollinger Bands are 17.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 07 Aug 2020
BioCryst Pharmaceuticals (BCRX) Q2 2020 Earnings Call Transcript - Nasdaq

Thu, 06 Aug 2020
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2020 Results - Earnings Call Transcript - Seeking Alpha

Thu, 06 Aug 2020
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

Thu, 06 Aug 2020
BioCryst: 2Q Earnings Snapshot - SFGate

Thu, 06 Aug 2020
BioCryst Reports Second Quarter 2020 Financial Results and Upcoming Key Milestones - GlobeNewswire

Wed, 05 Aug 2020
BioCryst Pharmaceuticals, Inc. (BCRX) Seems To Be Turning Some Investors Off - Invest Million

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 176
Shares Float (M) 135
% Held by Insiders 0.95
% Held by Institutions 90.20
Shares Short (K) 32,100
Shares Short P. Month (K) 18,430

Stock Financials

EPS -0.912
EPS Est This Year -0.750
EPS Est Next Year -0.780
Book Value (p.s.) 0.020
Profit Margin -241.66
Operating Margin -232.57
Return on Assets (ttm) -49.8
Return on Equity (ttm) -882.8
Qtrly Rev. Growth -18.1
Gross Profit (p.s.) -0.353
Sales Per Share 0.271
EBITDA (p.s.) -0.626
Qtrly Earnings Growth
Operating Cash Flow (M) -86
Levered Free Cash Flow (M) -47

Stock Valuations

PE Ratio -4.25
PEG Ratio
Price to Book value 194.00
Price to Sales 14.33
Price to Cash Flow -7.97

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.